Aurisco PharmaceuticalLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Aurisco PharmaceuticalLtd has a total shareholder equity of CN¥2.3B and total debt of CN¥847.3M, which brings its debt-to-equity ratio to 37.4%. Its total assets and total liabilities are CN¥3.7B and CN¥1.4B respectively. Aurisco PharmaceuticalLtd's EBIT is CN¥365.7M making its interest coverage ratio -18.1. It has cash and short-term investments of CN¥1.1B.
Anahtar bilgiler
37.4%
Borç/özkaynak oranı
CN¥847.28m
Borç
| Faiz karşılama oranı | -18.1x |
| Nakit | CN¥1.13b |
| Eşitlik | CN¥2.27b |
| Toplam yükümlülükler | CN¥1.42b |
| Toplam varlıklar | CN¥3.69b |
Son finansal sağlık güncellemeleri
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19
Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Recent updates
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?
Aug 14Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings
Jun 28Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings
May 12Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today
Apr 22Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 605116's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥537.8M).
Uzun Vadeli Yükümlülükler: 605116's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥884.9M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 605116 has more cash than its total debt.
Borcun Azaltılması: 605116's debt to equity ratio has increased from 0% to 37.4% over the past 5 years.
Borç Kapsamı: 605116's debt is well covered by operating cash flow (47%).
Faiz Kapsamı: 605116 earns more interest than it pays, so coverage of interest payments is not a concern.